The interactive transcript abundance index [c-myc*p73α]/[p21*Bcl-2] correlates with baseline level of apoptosis and response to CPT-11 in human bronchogenic carcinoma cell lines

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1553-1560

  Harr, Michael W ^a   Willey, James C ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Apoptosis; Bronchogenic carcinoma; CPT 11; Irinotecan; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN BCL 2; RNA PRECURSOR; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; HUMAN; LUNG CARCINOMA; LUNG TUMOR; NICK END LABELING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CARCINOMA, BRONCHOGENIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; IN SITU NICK-END LABELING; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA PRECURSORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34447262132     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1553     Document Type: Article

References (38)

1. Robles AI, Linke SP and Harris CC: The p53 network in lung carcinogenesis. Oncogene 21: 6898-6907, 2002.
2. Amundson SA, Myers TG and Fornace AJ: Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17: 3287-3299, 1998.
3. Lai SL, Perng RP and Hwang J: p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 7: 64-70, 2000.
4. Vousden KH and Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604, 2002.
5. Blanc C, Deveraux QL, Krajewski S, et al: Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 60: 4386-4390, 2000.
6. Nieves-Neira W and Pommier Y: Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int J Cancer 82: 396-404, 1999.
7. Miller LD, Smeds J, George J, et al: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102: 13550-13555, 2005.
8. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
9. Pizzolato JF and Saltz LB: The camptothecins. Lancet 361: 2235-2242, 2003.
10. Thomas CJ, Rahier NJ and Hecht SM: Camptothecin: current perspectives. Bioorg Med Chem 12: 1585-1604, 2004.
11. Schneider E, Hsiang YH and Liu LF: DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21: 149-183, 1990.
12. Hsiang YH, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989.
13. Cho LC and Choy H: Topoisomerase I inhibitors in the combined-modality therapy of lung cancer. Oncology 18: 29-39, 2004.
14. Xu Y and Villalona-Calero MA: Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13: 1841-1851, 2002.
15. Saijo N: Preclinical and clinical trials of topoisomerase inhibitors. Ann NY Acad Sci 922: 92-99, 2000.
16. Saijo N: Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan. Ann NY Acad Sci 803: 292-305, 1996.
17. Date H, Kiura K, Ueoka H, et al: Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer. Br J Cancer 86: 530-533, 2002.
18. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.
19. Ohtsuka K, Inoue S, Kameyama M, et al: Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer. Lung Cancer 41: 187-198, 2003.
20. Rasheed ZA and Rubin EH: Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22: 7296-7304, 2003.
21. Nakajima Y, Miyake S, Tanaka K, et al: The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: cell proliferation activity correlates with the effect of CPT-11. Cancer Sci 95: 464-468, 2004.
22. Pavillard V, Charasson V, Laroche-Clary A, Soubeyran I and Robert J: Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study. Anticancer Res 24: 579-585, 2004.
23. van Ark-Otte J, Kedde MA, van der Vijgh WJ, et al: Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 77: 2171-2176, 1998. (Pubitemid 28263937)
24. Seve P and Dumontet C: Chemoresistance in non-small cell lung cancer. Curr Med Chem Anti-Cancer Agents 5: 73-88, 2005.
25. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T and Tsuruo T: Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925-6930, 1990.
26. Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K and Harris CC: Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene 18: 3415-3421, 1999.
27. Nicholson SA, Okby NT, Khan MA, et al: Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 61: 5636-5643, 2001.
28. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614, 2002.
29. Wistuba, II, Gazdar AF and Minna JD: Molecular genetics of small cell lung carcinoma. Semin Oncol 28: 3-13, 2001.
30. You L, Yang CT and Jablons DM: ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 60: 1009-1013, 2000.
31. Bernasconi NL, Wormhoudt TA and Laird-Offringa IA: Post-transcriptional deregulation of myc genes in lung cancer cell lines. Am J Respir Cell Mol Biol 23: 560-565, 2000.
32. Gao N, Hu YD, Cao XY, Zhou J and Cao SL: The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines. J Cancer Res Clin Oncol 127: 359-367, 2001.
33. Augenlicht LH, Wadler S, Corner G, et al: Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57: 1769-1775, 1997.
34. Wang S, Nath N, Fusaro G and Chellappan S: Rb and prohibitin target distinct regions of E2F1 for repression and respond to different upstream signals. Mol Cell Biol 19: 7447-7460, 1999.
35. Yu X, Guo ZS, Marcu MG, et al: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94: 504-513, 2002.
36. El-Deiry WS, Harper JW, O'Connor PM, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
37. Han Z, Wei W, Dunaway S, et al: Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem 277: 17154-17160, 2002.
38. Harms K, Nozell S and Chen X: The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 61: 822-842, 2004.